念珠菌症治療藥市場 - 成長，趨勢，及預測(2019年 - 2024年)
Candidiasis Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
|出版商||Mordor Intelligence LLP||商品編碼||871440|
|出版日期||內容資訊||英文 115 Pages
|念珠菌症治療藥市場 - 成長，趨勢，及預測(2019年 - 2024年) Candidiasis Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)|
|出版日期: 2019年05月01日||內容資訊: 英文 115 Pages||
The candidiasis therapeutics market is expected to witness rapid growth due to the increase in the number of patients affected by candidiasis infection, increasing the susceptible immune compromised patient pool and growing awareness for candidiasis infection.
There has been an increase in the number of patients affected by candidiasis infection in the developing markets that are expected to boost the overall market growth over the forecast period. The Center for Disease Control and Prevention (CDC) estimates that approximately 46,000 cases of healthcare-associated invasive candidiasis occur each year, in the United States. CDC reports that the 30-day all-cause (crude) mortality among people with candidemia is approximately 30%. However, as people who develop invasive candidiasis typically have pre-medical conditions, it is generally ambiguous to determine the proportion of deaths directly attributable to the infection. This increase in the number of patients has helped in spurring the growth of the overall market. The increasing of urbanization and rising hygiene awareness in developing countries also helps in the growth of the market.
As per the scope of the report, candidiasis is commonly a fungal infection that affects men and women both of all age groups. It is also known as candidosis, moniliasis, and oidiomycosis. The effects of this infection are seen on a dermal, internal and systemic level wherein it is known as candidemia or intestinal thrush. The market is dynamic due to the widespread occurrence of this disease. The major drug classes for treatment include azoles, polyenes, and echinocandins.
Systemic Candidiasis is Anticipated to be the Dominant Segment in Anatomy Type During the Forecast Period
The market for systemic candidiasis is found to be driven by the increase in the susceptible immune compromised patient pool. Thrush occurs in approximately 2-5 percent of healthy newborn and affects them mainly during their first year of life. Over 1 million adult women and adolescent girls in the US develop vaginal yeast infections each year. Therefore the high incidence of candidiasis is expected to remain a major driver for the growth of the market during the forecast period.
North America Region Holds the Largest Market Share of Candidiasis Therapeutics Market
Due to the high investment in healthcare and awareness of diseases, the North American segment of the market studied is estimated to account for the highest market share. The candidiasis disease is found growing rapidly in the US and is not restricted to any particular region. It has also been found that the North America and Europe region has been accountable for the largest markets revenue share due to a higher awareness of the disease amongst individuals and also the availability of better treatment. Hence all these factors are associated with the growth of the market.
The major companies present in the market are found focusing on product innovations, expansions, finding new markets or innovating their core competency to expand their individual market share.